Human epidermal growth factor receptor targeted inhibitors for the treatment of ovarian cancer

Ovarian cancer is the second most lethal gynecological cancer worldwide and while most patients respond to initial therapy, they often relapse with resistant disease. Human epidermal growth factor receptors (especially HER1/EGFR and HER2/ERBB2) are involved in disease progression; hence, strategies...

Descripción completa

Detalles Bibliográficos
Autores principales: Bonello, Maria, Sims, Andrew Harvey, Langdon, Simon Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Chinese Anti-Cancer Association 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6372909/
https://www.ncbi.nlm.nih.gov/pubmed/30766749
http://dx.doi.org/10.20892/j.issn.2095-3941.2018.0062

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6372909/
https://www.ncbi.nlm.nih.gov/pubmed/30766749
http://dx.doi.org/10.20892/j.issn.2095-3941.2018.0062

Ejemplares similares